Ridaforolimus (AP23573/MK-8669) in Participants With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)(MK-8669-017)

Prostate Cancer Clinical Trial

Official title:

A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00110188
• Other study ID #: 8669-017
• Secondary ID: AP23573-04-204
• Status: Completed
• Phase: Phase 2
• First received: May 4, 2005
• Last updated: November 18, 2015
• Start date: May 2005
• Est. completion date: August 2007

Study information

• Verified date: November 2015
• Source: Merck Sharp & Dohme Corp.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the antitumor activity of weekly ridaforolimus study treatment in participants with taxane-resistant AIPC.

Description:

The primary objective of this phase II study is to assess the anti-cancer activity of weekly ridaforolimus administration in participants with taxane-resistant AIPC. Other objectives include evaluating experimental parameters that may predict or indicate response to mTOR inhibition, such as effects on plasma VEGF, markers of tumoral PI3K/mTOR-pathway activity, and proteomic analysis. The inclusion of these evaluations in this trial may provide insight into the identification of markers that may be helpful in optimizing ridaforolimus treatment and in identifying patients with ridaforolimus-sensitive tumors.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: August 2007
• Est. primary completion date: April 2007
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male patients aged = 18 years with histologically documented adenocarcinoma of the prostate.

• Clinically refractory to hormone therapy (orchiectomy or luteinizing hormone-releasing hormone agonist/antagonist).

• Presence of metastatic prostate cancer that fulfills at least one evaluation category as listed: * Measurable Disease: Lesion(s) that can be accurately measured in at least one dimension with the longest diameter = 20 mm using conventional techniques or = 10 mm with spiral CT scan (or otherwise at least twice the reconstruction interval for CT or MRI scans). *Non-measurable disease: Lesions noted on imaging studies (including metastatic bone lesions on bone scan) or other non-measurable lesions as defined by the modified RECIST criteria. *Progressive disease following a cytotoxic chemotherapy regimen for prostate cancer.

• Previous treatment with at least one taxane-containing chemotherapy regimen. Patients may have received treatment with not more than 3 additional regimens of cytotoxic chemotherapy prior to study entry.

• Orchiectomy, or castrate levels of testosterone maintained by LHRH agonist/antagonist < 50 ng/mL.

• Predicted life expectancy > 12 weeks.

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 2.

• Adequate renal and hepatic function, defined as: *Total serum bilirubin = 1.5 x ULN for the institution; *AST and/or ALT = 3 x ULN for the institution (= 5 x ULN if liver metastases are present); *Serum albumin = 2.5 g/dL; *Serum creatinine =1.5 x ULN for the institution (or a calculated creatinine clearance = 50 mL/min/1.73m2)

• Adequate bone marrow function, defined as: *ANC = 1.5 x 10^9/L; *Platelet count = 100 x 10^9/L

• Serum cholesterol < 350 mg/dL and triglycerides < 400 mg/dL.

• Male patients who are not surgically sterile must agree to use reliable methods of birth control for the duration of the study until 30 days after the last dose of study drug.

• Able to understand and give written informed consent.

Exclusion Criteria:

• Presence of active or progressive brain metastases.

• Prior therapy with rapamycin, rapamycin analogues or tacrolimus.

• Prior non-hormonal anticancer treatment (chemotherapy, radiotherapy, immunotherapy, biological response modifiers, signal transduction inhibitors, etc.) within 4 weeks prior to the first dose of ridaforolimus

• Ongoing toxicity associated with prior anticancer therapy (except peripheral neuropathy of = grade 1 by NCI toxicity criteria).

• Another primary malignancy within the past three years (except for non-melanoma skin cancer).

• Known or suspected hypersensitivity to drugs formulated with polysorbate 80 (Tween) or any other excipient contained in the study drug.

• Known Grade 3 or 4 hypersensitivity to macrolide antibiotics (e.g., clarithromycin, erythromycin, azithromycin).

• Significant uncontrolled cardiovascular disease.

• Active infection requiring systemic therapy.

• Known HIV infection.

• Treatment with any investigational agent within 4 weeks prior to the first dose of ridaforolimus

• Concurrent treatment with immunosuppressive agents other than prescribed corticosteroids at stable doses for = 2 weeks prior to first planned dose of study drug.

• Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 2 weeks prior to the first dose of ridaforolimus

• Presence of any other life-threatening illness or organ system dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with evaluating the safety of the study drug.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• ridaforolimus

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center/MGH/DFCI	Boston	Massachusetts
United States	The Methodist Hospital Research Institute	Houston	Texas
United States	Louis Warchaw Prostate Cancer Center, Cedars-Sinai Medical Center	Los Angeles	California
United States	University of Wisconsin, Madison, WI	Madison	Wisconsin

Sponsors (2)

Lead Sponsor	Collaborator
Merck Sharp & Dohme Corp.	Ariad Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Best Overall Response (BOR) per Response Evaluation Criteria in Solid Tumors (RECIST)		Up to 24 months	No
Secondary	Number of Participants Experiencing at Least One Adverse Event		Up to 25 months	Yes
Secondary	Change from Baseline in Prostate-Specific Antigen (PSA)		Baseline and up to 24 months	No
Secondary	Time to Tumor Progression (TTP)		Up to 24 months	No
Secondary	Progression-Free Survival (PFS)		Up to 24 months	No
Secondary	Overall Survival (OS)		Up to 24 months	No
Secondary	Duration of Response (DOR)		Up to 24 months	No
Secondary	Change from Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Score		Baseline and up to 24 months	No
Secondary	Change from Baseline in Plasma Vascular Endothelial Growth Factor (VEGF)		Baseline and Day 28 of Cycles 1 and 2 (Up to 56 days)	No